Skip to main content
ACR Convergence 2025 Main banner
Final Program


Schedule at a Glance
Legend
Presentation Icons
CME
CME
Non-CME
Non-CME
In Person
In Person
On Demand
On Demand
Live Stream
Live Stream
Active Learning
Active Learning
Choose Rheum
Choose Rheum
Emerging Investigator Awardee
Emerging Investigator Awardee

  1. Home

  • Sunday, Oct 26th
    9:00 AM - 10:00 AM Central Time
    26S13: Crystal Clear Solutions in CPPD
    Location: S102
    Moderator: Angelo Gaffo, MD, FACP – University of Alabama at Birmingham
    Moderator: Puja Khanna, MD, MPH – University of Michigan
    Session Coordinator: Angelo Gaffo, MD, FACP – University of Alabama at Birmingham
    Session Coordinator: Puja Khanna, MD, MPH – University of Michigan
     CE: 1.00
  • Sunday, Oct 26th
    9:00 AM - 9:30 AM Central Time
    Shining the Light: Diagnosing and Understanding CPPD with Clarity
    Location: S102
    Speaker: Sara Tedeschi, MD, MPH – Brigham and Women's Hospital
  • Sunday, Oct 26th
    9:30 AM - 10:00 AM Central Time
    Cracking the Crystal Code: Therapeutic Advances in CPPD
    Location: S102
    Speaker: Tristan Pascart, MD, PhD (he/him/his) – Lille Catholic University
  • Monday, Oct 27th
    8:00 AM - 9:30 AM Central Time
    27M03: Gazing into the Crystal Ball: Gout and Cardiometabolic Comorbidity Management
    Location: W190A-B
    Moderator: Michael Toprover, MD – New York University Langone Health
    Moderator: Puja Khanna, MD, MPH – University of Michigan
    Session Coordinator: Michael Toprover, MD – New York University Langone Health
    Session Coordinator: Puja Khanna, MD, MPH – University of Michigan
    Session Coordinator: Naomi Schlesinger, MD – University of Utah
     CE: 1.50
  • Monday, Oct 27th
    8:00 AM - 8:30 AM Central Time
    The Metabolic Syndrome and Development of Gout
    Location: W190A-B
    Speaker: Natalie McCormick, PhD – Massachusetts General Hospital
  • Monday, Oct 27th
    8:30 AM - 9:00 AM Central Time
    Cardiovascular Morbidity and Mortality in Gout Patients
    Location: W190A-B
    Speaker: Jasvinder Singh, MD,MPH – Baylor College of Medicine
  • Monday, Oct 27th
    9:00 AM - 9:30 AM Central Time
    Treatments of Gout and its Metabolic Risk Factors
    Location: W190A-B
    Speaker: Naomi Schlesinger, MD – University of Utah
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I
    Location: Hall F1
     CE: 0.00
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1125: Validation of an Allopurinol Dose Prediction Tool to Achieve Goal Serum Urate Among Patients with Gout
    Location: Hall F1
    Abstract Poster Presenter: Brian Coburn, MD, PhD – University of Pennsylvania
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1123: Nanoencapsulated Sirolimus plus Pegadricase (NASP) Demonstrates Long Term Efficacy and Safety in Patients with Uncontrolled Gout: Results from the 24-week Double-blind Extension of the Phase 3 DISSOLVE I Study
    Location: Hall F1
    Abstract Poster Presenter: Alan Kivitz, MD, MACR – Altoona Center for Clinical Research
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1126: Clinical Impact of Signs of Calcium Pyrophosphate Deposition Disease (CPPD) on Radiographs of Hands and Wrists in a Real-World Cohort of Patients with Early Rheumatoid Arthritis
    Location: Hall F1
    Abstract Poster Presenter: Coralie Tremblay, MD (she/her/hers) – University of Sherbrooke
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1133: A Proteomic Analysis of Subclinical Synovial Inflammation Associated with Monosodium Urate Crystal Deposition
    Location: Hall F1
    Abstract Poster Presenter: Mariano Andrés, PhD – Dr Balmis Alicante General University Hospital-ISABIAL
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1143: Gout and Renal Failure-Related Mortality Trends in USA from 1999-2020: Analysis of CDC Wonder Database
    Location: Hall F1
    Abstract Poster Presenter: Shiamak Cooper, MD – Rochester General Hospital
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1144: A Quantitative Study of Renal Medulla Echogenicity in 250 Vietnames Gout Patients Shows Correlation with Poor Renal Function
    Location: Hall F1
    Abstract Poster Presenter: Thomas Bardin, MD – Lariboisiere Hospital, Department of Rheumatology
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1132: DDX3X Regulates Gout Inflammation via NLRP3 Inflammasome Activation and Macrophage Pyroptosis Crosstalk
    Location: Hall F1
    Abstract Poster Presenter: linrui zhong, MMed – North Sichuan Medical College
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1134: Efficacy and Safety of Anakinra for Acute Calcium Pyrophosphate Deposition Disease Flare: A Systematic Review and Meta-Analysis
    Location: Hall F1
    Abstract Poster Presenter: Pannathorn Nakaphan, MD (he/him/his) – Weiss Memorial Hospital
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1140: PGG Suppresses MSU Crystal–Triggered Inflammation and Arachidonic Acid Production in PBMCs
    Location: Hall F1
    Abstract Poster Presenter: Sadiq Umar, PhD – University of Illinois at Chicago
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1129: Effectiveness of sodium-glucose cotransporter type 2 inhibitors and urate-lowering agents in patients with gout: data from a single-center specialised clinic
    Location: Hall F1
    Abstract Poster Presenter: Jose María Doménech Serrano, MD – Hospital Doctor Balmis Alicante
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1130: Novel Anti-Obesity Medications and Serum Urate Change Among Patients with Gout and Baseline Hyperuricemia
    Location: Hall F1
    Abstract Poster Presenter: Kiara Tan, BA – Massachusetts General Hospital
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1137: Increased Risk of Cardiovascular Events and Mortality Related to Diffuse Idiopathic Skeletal Hyperostosis (DISH): A Systematic Review and Meta-Analysis
    Location: Hall F1
    Abstract Poster Presenter: Pitchaporn Yingchoncharoen, MD (she/her/hers) – University of Missouri
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1141: Modulation of Inflammatory Responses by Dental Pulp Stem Cell Extracellular Vesicles in Monosodium Urate-Stimulated Macrophages
    Location: Hall F1
    Abstract Poster Presenter: Sadiq Umar, PhD – University of Illinois at Chicago
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1131: Variant Drives Tophus Formation through Dual Mechanisms: Extracellular Aggregation andvImpaired Macrophage Phagocytic Clearance
    Location: Hall F1
    Abstract Poster Presenter: LEI LIU, MD – The Second Hospital affiliated to Zhejiang University, College of Medicine
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1139: Synovial Counts, Cultures, and Crystals: An Analysis of 9,000 Aspirations
    Location: Hall F1
    Abstract Poster Presenter: Sabahat Usmani, MD (she/her/hers) – Medical College of Wisconsin
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1128: Association Between Leptin Levels, Body Mass Index and Health-related Quality of Life in Patients with Gout
    Location: Hall F1
    Abstract Poster Presenter: Inna Orlova, MD, PhD (she/her/hers) – National Pirogov Memorial Medical University, Vinnytsya
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1127: The Pathogenetic Role of Calcium Pyrophosphate and Basic Calcium Phosphate Crystals in Osteoarthritis: Associations with Synovial Fluid Cytokines and Clinical Indices
    Location: Hall F1
    Abstract Poster Presenter: Francesca Oliviero, PhD, MS, PharmD (she/her/hers) – Rheumatology Unit, Department of Medicine - DIMED, University of Padova
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1146: Association of Walking Volume and Intensity with Incident Gout: A Population-based Cohort Study
    Location: Hall F1
    Abstract Poster Presenter: Ziying Wu, MD, PhD – Xiangya Hospital Central South University
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1135: A Gain-of-function 5’UTR Variant in ANKH Causes Familial CPPD with Elevated Extracellular Ppi and Citrate
    Location: Hall F1
    Abstract Poster Presenter: Pascal Richette, MD – Lariboisière Hospital
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1124: ABCG2 Variants as Genetic Risk Factors for Hyperuricemia and Gout: Focus on Pediatric and Familial Manifestations
    Location: Hall F1
    Abstract Poster Presenter: Blanka Stiburkova, n/a (she/her/hers) – Institute of Rheumatology
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1136: The Impact of Iron Overload and HFE Genetic Mutations on Joint Disease in Haemochromatosis: Data from the Haemochromatosis Arthropathy Inception Cohorts
    Location: Hall F1
    Abstract Poster Presenter: Patrick Kiely, MD,PhD,MBBS,BSc,FRCP (he/him/his) – St George's University Hospitals NHS Foundation Trust
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1138: Efficacy of Pozdeutinurad (AR882) in Treatment Naïve and Suboptimally Treated Gouty Arthritis with Tophi
    Location: Hall F1
    Abstract Poster Presenter: Robert Keenan, MD – Arthrosi Therapeutics
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1142: Tibial Bone Microstructure and Histomorphometry in Individuals with CPPD
    Location: Hall F1
    Abstract Poster Presenter: Sara Tedeschi, MD, MPH – Brigham and Women's Hospital
  • Monday, Oct 27th
    10:30 AM - 12:30 PM Central Time
    1145: Numerically Reduced but MSU Crystal-Activated NK Cells Promote Osteoclastogenesis in Gout
    Location: Hall F1
    Abstract Poster Presenter: Yong-Wook Park, MD, PhD – Department of Rheumatology, Chonnam National University Medical School and Hospital
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster II
    Location: Hall F1
     CE: 0.00
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2003: Evaluating Patient Outcomes Pre and Post Pegloticase Initiation among Uncontrolled Gout Patients: Findings from MORE2 Registry and Medicare Fee-For-Service Claims Data
    Location: Hall F1
    Abstract Poster Presenter: Julia Buchfuhrer, DO – JB Arthritis and Rheumatology Center
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    1992: Tolerance of Methotrexate Coadministered with Pegloticase in Patients with Uncontrolled Gout: Findings from MIRROR RCT
    Location: Hall F1
    Abstract Poster Presenter: Brian LaMoreaux, MD;MS – Amgen, Inc.
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    1998: Reduction in Tophi Observed in Patients with Uncontrolled Gout Treated with NASP: Results from Phase 3 DISSOLVE Studies
    Location: Hall F1
    Abstract Poster Presenter: Herbert Baraf, MD, FACP, MACR – National Institute of Arthritis and Musculoskeletal and Skin Diseases
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    1993: Risk of Cardiovascular Conditions, Bone Fractures and Mortality in Patients with Uncontrolled Gout in Comparison to Those with Controlled Gout
    Location: Hall F1
    Abstract Poster Presenter: Brian LaMoreaux, MD;MS – Amgen, Inc.
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2009: Value of New PREVENT Calculator in Detecting Cardiovascular Disease in Patients with Gout
    Location: Hall F1
    Abstract Poster Presenter: Patrick Williamson, MD (he/him/his) – UAB Internal Medicine Residency
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    1999: Characterization of Infusion Reactions Within 1 Hour of Treatment With Nanoencapsulated Sirolimus Plus Pegadricase: Pooled Results From the Phase 3 DISSOLVE I and DISSOLVE II Trials
    Location: Hall F1
    Abstract Poster Presenter: Herbert Baraf, MD, FACP, MACR – National Institute of Arthritis and Musculoskeletal and Skin Diseases
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2007: Machine Learning-Based Prediction of Gout Onset in Individuals with Asymptomatic Hyperuricemia Using a Common Data Model
    Location: Hall F1
    Abstract Poster Presenter: Min Jung Kim, MD – Seoul Metropolitan Government Boramae Medical center
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2010: Innate Transcriptional Response and Control of Expression of the Gout-Associated Colony Stimulating Factor-1 (CSF1) and CSF1 Receptor (CSF1R) Genes to Stimuli
    Location: Hall F1
    Abstract Poster Presenter: Tony Merriman, PhD – University of Alabama at Birmingham
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2004: Characteristics and Management of Gout Patients Under Rheumatologist Care from Low-Income and Middle-Income Asia-Pacific Countries: Data from the APLAR Gout Registry
    Location: Hall F1
    Abstract Poster Presenter: Kanon Jatuworapruk, MD – Thammasat University
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2005: Elevated Serum Uric Acid as an Independent Risk Factor for Multiple Stent Placement in Non-Hypertensive, Non-Diabetic Patients with Coronary Artery Disease: A Retrospective Cohort Analysis
    Location: Hall F1
    Abstract Poster Presenter: Lemei An, MD – Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Henan University People's Hospital
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    1990: Pilot Study: Testing the Accuracy of a Capillary Point-of-Care Device Compared to Traditional Venous Analysis for Serum Urate Measurements Among Patients with Gout
    Location: Hall F1
    Abstract Poster Presenter: Alex Tinianow, MD – Vanderbilt University Medical Center
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    1994: Pharmacokinetics of Ready-to-Use Pegloticase Formulation Compared to Standard Pegloticase Dosing: Data from the AGILE Study
    Location: Hall F1
    Abstract Poster Presenter: Brian LaMoreaux, MD;MS – Amgen, Inc.
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    1997: Bone health in patients with gout using real-world U.S. data
    Location: Hall F1
    Abstract Poster Presenter: Emily Holladay, MPH – University of Alabama at Birmingham
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    1995: The Prevalence of Multimorbidity and Polypharmacy Among US Adults with Gout: A General Population-Based Study
    Location: Hall F1
    Abstract Poster Presenter: Chio Yokose, MD, MSc (she/her/hers) – Massachusetts General Hospital
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2013: Efficacy and Safety of Firsekibart in Acute Gouty Arthritis Patients with Limited Treatment Options: A Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled Phase III Trial
    Location: Hall F1
    Abstract Poster Presenter: Yu Xue, MD – Huashan Hospital,Fudan University
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    1996: Hospital Burden of Crystal-related Arthritis in Spain: a nationwide dataset of 183,001 inpatients.
    Location: Hall F1
    Abstract Poster Presenter: Cristina Rodríguez Alvear, III, -None- – Hospital Doctor José Molina Orosa
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2014: Efficacy and Safety of Firsekibart in Acute Gouty Arthritis Patients with eGFR < 60ml/min/1.73m2:A Post-Hoc Analysis of 24-Week Data
    Location: Hall F1
    Abstract Poster Presenter: Yu Xue, MD – Huashan Hospital,Fudan University
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2014: Efficacy and Safety of Firsekibart in Acute Gouty Arthritis Patients with eGFR < 60ml/min/1.73m2:A Post-Hoc Analysis of 24-Week Data
    Location: Hall F1
    Abstract Poster Presenter: Yu Xue, MD – Huashan Hospital,Fudan University
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2000: Can Uric Acid Protect Joints? Lower Incidence of Large Joint Replacements Among Individuals with Higher SUA
    Location: Hall F1
    Abstract Poster Presenter: Janis Timsans, MD – Päijät-Häme Central Hospital, Department of Rheumatology
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    1991: Co-Use of Mycophenolate Mofetil with Pegloticase Yielded Similar Clinical Outcomes as the Co-Use of Methotrexate
    Location: Hall F1
    Abstract Poster Presenter: Bradley Marder, MD – AMGEN, Inc
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2006: Storytelling and Navigation to Improve Gout Follow-up: A Multicenter, Randomized Controlled Trial
    Location: Hall F1
    Abstract Poster Presenter: Lesley Jackson, MD, MSPH – University of Alabama at Birmingham
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2001: Characteristics of Gout Flares Over Time with Treat-to-Target Urate-Lowering Therapy Use
    Location: Hall F1
    Abstract Poster Presenter: Jason Yang, MD, PhD (he/him/his) – Boston Medical Center
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2008: Exposure to Anaerobic Antibiotics and Risk of Gout Flares: Target Trial Emulation for the Potential Role of the Gut Microbiome in Gout and Chronic Kidney Disease (CKD)
    Location: Hall F1
    Abstract Poster Presenter: Natalie McCormick, PhD – Massachusetts General Hospital
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2011: A Phase 1 Placebo Controlled, Single (SAD) and Multiple Dose Escalation (MAD) Safety and Pharmacokinetic (PK) Study of a Novel Colchicine Analogue ABP-745 in Healthy Volunteers (HV)
    Location: Hall F1
    Abstract Poster Presenter: Ullrich Schwertschlag, MD, PhD (he/him/his) – Atom Therapeutics
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2012: A Phase 2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses of ABP-671 in Subjects with Hyperuricemia or Gout in China
    Location: Hall F1
    Abstract Poster Presenter: Ullrich Schwertschlag, MD, PhD (he/him/his) – Atom Therapeutics
  • Tuesday, Oct 28th
    10:30 AM - 12:30 PM Central Time
    2002: Methods to Address Survival Bias and Competing Risks in Estimating the Causal Risks of Gout on Dementia Risk
    Location: Hall F1
    Abstract Poster Presenter: Joshua Baker, MD, MS – University of Pennsylvania
  • Tuesday, Oct 28th
    1:00 PM - 2:30 PM Central Time
    28T33: Abstracts: Metabolic & Crystal Arthropathies – Basic & Clinical Science
    Location: S102
    Abstract Moderator: Naomi Schlesinger, MD – University of Utah
    Abstract Moderator: Hyon K. Choi, MD, MPH, DrPH – MASSACHUSETTS GENERAL HOSPITAL
     CE: 0.00
  • Tuesday, Oct 28th
    1:00 PM - 1:15 PM Central Time
    2585: The effect of prophylactic colchicine use on gene expression in gout
    Location: S102
    Presenting Author: Austin Wheeler, MD (he/him/his) – University of Nebraska Medical Center
  • Tuesday, Oct 28th
    1:15 PM - 1:30 PM Central Time
    2586: Estimated Carrier Prevalence of HLA-B*58:01 Across Diverse Populations in the US and Globally
    Location: S102
    Presenting Author: Qiping Xu, MD – Mayo Clinic Health System - Mankato
  • Tuesday, Oct 28th
    1:30 PM - 1:45 PM Central Time
    2587: Nanoencapsulated Sirolimus Plus Pegadricase Reduced Disease Burden in Patients With Uncontrolled Gout: Results From the Phase 3 DISSOLVE Trials
    Location: S102
    Presenting Author: Puja Khanna, MD, MPH – University of Michigan
  • Tuesday, Oct 28th
    1:45 PM - 2:00 PM Central Time
    2588: Nanoencapsulated Sirolimus plus Pegadricase (NASP) Demonstrates a Reduction in Gout Flares: Results from the Phase 3 DISSOLVE Studies
    Location: S102
    Presenting Author: Angelo Gaffo, MD, FACP – University of Alabama at Birmingham
  • Tuesday, Oct 28th
    2:00 PM - 2:15 PM Central Time
    2589: Multi-omics Integration Reveals Gut Microbiota–Metabolite Dysregulation in Gout with Metabolic Syndrome
    Location: S102
    Presenting Author: Yuanpiao Ni, MMed (he/him/his) – North Sichuan Medical College
  • Tuesday, Oct 28th
    2:15 PM - 2:30 PM Central Time
    2590: Translating findings on urate-metabolizing bacterial genes and urate levels at the human population level: a gut microbiome analysis of three independent cohorts of men and women
    Location: S102
    Presenting Author: Sharan Rai, PhD – Massachusetts General Hospital, Harvard Medical School